Nuclea taps Enzo to distribute metastatic breast cancer test

02/19/2014 | GenomeWeb Daily News (free registration)

Nuclea Biotechnologies has agreed to allow Enzo Clinical Labs to offer its HER-2/neu serum assay for undisclosed terms. The assay, which uses blood samples, is designed to help doctors monitor metastatic breast cancer in women whose tumors contain the HER-2/neu protein and make treatment decisions based on the outcomes.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY